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Physiology of Bone: Mineral
Compartment Proteins As Candidates for
Environmental Perturbation by Lead
by John J. Sauk* and Martha J. Somermant
Termine et al. first demonstrated that sequential dissociative extraction and fractionation proce-
dures with protease inhibitors could provide a convenient approach for the study of mineral com-
partment constituents. The primary extraction regimen used 4 M guanidine HCI to remove most of
the protein from the nonmineralized phase of bone. Subsequently, EDTA-guanidine was used to re-
move the mineral-phase components. These methods discriminate on the basis ofphysical-chemical
association with a mineral phase rather than on the specific gene products of a particular cell. In
the present discussion emphasis is directed at a group of divalent cation binding proteins isolated
from the mineral compartment ofbone. The localization, synthesis, and chemical characteristics of
osteonectin, bone sialoproteins I and II, and bone acidic glycoprotein-75 are discussed and offered
as possible sites for perturbation by the environment with lead exposure.
Introduction
The cumulative effects of exposure to an environ-
ment can be expressed as alterations in cellular prod-
ucts and canbe preserved inthe mineralized tissues of
an organism. Tothis end, archeological specimens and
skeletal rudiments have been shown to harbor ele-
ments common to an organism's exposure. Included
among these elements is the inorganic element lead.
The reliability ofthe record maintained within these
tissues depends in great part upon the degree of re-
modeling to which the matrices are subjected and the
site from which the samples are obtained (1). Bone is a
complex tissue consisting ofmineral, cells, and an ex-
tracellular matrix composed of collagenous and non-
collagenous proteins, all ofwhich are subject to proces-
sing as a function ofdevelopment and growth.
There is considerable evidence that noncollagenous
matrix proteins associated with bone are important in
the regulation ofbone homeostasis, although the pre-
cise role ofspecificproteins has notyetbeenelucidated
(1-4). Our understanding ofthe matrix components of
mineralized tissue have benefitted from advances in
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extraction and fractionation procedures performed in
the presence ofprotease inhibitors (5). In essence, pri-
maryextraction ofmineralizedmatriceswith dissocia-
tive agents such as 4 M guanidine HCl removes many
ofthe proteins from the mineral phase ofthese matri-
ces. Subsequent extractionwithguanidine HCl/EDTA
dissolutesthe mineral phase andextractsthe strongly
mineral binding noncollagenous proteins considered
to have important functions in maintaining bone
homeostasis. Thus, many studieshavebeendirectedat
understanding the properties ofthese proteins.
Forexample, in attempts tounderstandthe effects of
these extracellular matrix proteins on the osteogenic
process, ademineralizedmatrix,containingallthefac-
tors necessary for mineralization, hasbeenused(6-8).
In this system, demineralized bone matrix power im-
planted subcutaneously in rats induces new bone for-
mation in a sequential manner analogous to fracture
healing (9). After the initial influx ofpolymorphonu-
clear leukocytes, mesenchymal cells are attracted to
the site, where they subsequently attach, spread, pro-
liferate, and synthesize the appropriate matrix re-
quiredfortheformationofcartilage andbone. Thefact
that an initial event in this process is the migration,
followedbyattachment ofcellstothesite, stronglysup-
ports the concept that migration and attachment are
directed via specific signals. In support ofthis, several
chemotacticfactors(10-13), aswell as attachment pro-
teins, have been identified in guanidine/EDTA ex-
tracts ofbone (14-18).
In addition, several factors and proteins extracted
from mineralized tissues, e.g., bone morphogenic pro-SAUKAND SOMERMAN
tein, growth factors, and osteonectin, have been impli-
cated as having a role in initiation of mineralization
(1-5). In this article the properties ofbone-associated
attachment proteins are discussed. Also, osteonectin/
SPARC/BM-40, aproteinfirst identified inbone(5,19),
is reviewed. These proteins were selected not only be-
cause of their potential importance to maintaining
mineral homeostasis, but also because oftheir poten-
tial to be modulated by cationic metals, such as lead.
All the proteins discussed below are cation-binding
proteins requiring solvents containing EDTA for ex-
traction.
Osteonectin/SPARC/BM-40
Osteonectin is a 32-kilodalton (kDa) glycoprotein
composedofasingle polypeptide chainwith several in-
tramolecular disulfide bonds (19-21). This protein is
one of the principal noncollagenous proteins of bone
(19-22). Osteonectin is synthesized by osteoblastlike
cells inculture (23,24)and is secreted as anextracellu-
lar matrix protein in the cell layer (26,27). In vitro
binding studies have revealed that osteonectin has a
high affinity for calcium (Kd = 3 x 10-7 M), hydroxy-
apatite (Kd = 8 x 10-8 M), and collagen (20,21,28). The
affinity of osteonectin for hydroxyapatite is six times
strongerthanthatofboneGlaprotein(BGP,alsocalled
osteocalcin) (25). These data have been interpreted to
indicate that osteonectin mayhave an important func-
tion in bone (1). Similar, ifnot identical, proteins have
been derived from nonmineralized tissues and by se-
quence analysis showntohavehighhomology withthe
protein derivedfrombone (26). Stenner et al. (27) have
described an analogous protein in platelets, and Dzia-
deketal. (28)identified abasement membrane protein
(BM40)from mouse EHS tumorsthat appears identical
to osteonectin. The protein termed SPARC (secreted
protein, acidic rich in cysteine) derived from mouse
parietal endoderm (29,30) manifests significant ho-
mology withthebone-derived protein asdoes a 43 kDa
protein secreted by bovine endothelial cells in culture
(31). The presence oftheseproteins innonmineralizing
tissues queries the possible physiological role that
these moleculesplay in nonosseous matrices. The min-
eral binding properties of osteonectin make it an im-
portant candidate for environmental perturbations
with other cations.
Bolander et al. (26) have recently sequenced the bo-
vineosteonectin molecule. Thenucleotide sequence ob-
tained from these studies revealed that osteonectin
contains 304 aminoacids, with a 17-residuesignalpep-
tide. Structural analysis deduced from this sequence
indicated that osteonectin contains at least four do-
mains. The amino terminus ofthe protein appears to
harbor a potential hydroxyapatite binding site. The
next domain, a cysteine-rich area, has a sequence ho-
mology with the cysteine-rich domain in turkey ovo-
mucoid, bovine acrosyn inhibitor, and bovine pancre-
atic trypsin inhibitor. The carboxyl halfofthe protein
contains two sequence homologies with central cal-
cium-binding loops, "EF hands," with the potential of
being high-affinity calcium binding sites (26).
Recently, McVey et al. (32) have shown that the
SPARC/osteonectin gene contains 10 exons and covers
26.5 kilobasepairsofDNA.Findlayetal. (33)extended
these studies and demonstrated that interspecies dif-
ferences probably reside in a exon at the N-terminus.
Analyses ofthe remaining exons revealed that two N-
terminal glutamic acid-rich sequences predicted to
undergo conformational change upon binding of cal-
cium and the EF-hand Ca2` binding domain are each
encoded by a single exon. It was concluded that the
SPARC gene probably has not evolved by shuffling of
exons from other Ca2` binding proteins (33). It is note-
worthythatwhenthe 5'flankingregionoftheSPARC/
osteonectin gene was placed in front of the bacterial
chloramphenicol acetyltransferase gene, neither TATA
norCCAATbox sequences were detected. However, un-
like most othergeneslackingthese motifs, mappingof
the 5' end of the SPARC/osteonectin gene by RNAse
protection and primer extension analysis revealed only
a single major and one minor transcription start site
(32). Youngetal. (34)notedthatheterogeneity observed
at the 5' end of the gene may be due to a lack of a
CCAAT or TATA box believed to be involved in posi-
tioning ofRNA polymerase (35). In addition, nine se-
quence motifs have been identified in the osteonectin
gene(34). Thesemotifsinclude a)TAATassociatedwith
growth hormone responsiveness (36); b) GAANNTTC,
a heat shock element(37); c) TCAGAG, responsible for
cAMP action (39); d) TGCACTC, regulating metal re-
sponsiveness (39); e) CCAAT, associated with CCAAT
protein binding(40); ) TCGNNNNGCCAA, NFI bind--...__.X::Wo....A.;$;;t....,_.'*
* ., : . ............................... .. ..
'AZ '/
:A...e...._-.
FIGURE 1. Western blot using rabbit-anti-bovine osteonectin anti-
bodies (courtesy of L. W. Fisher, NIH/NIDR). (A) Control cells
grown on tissue culture plates. (B) Osteoligament cells treated
with 5 mML-azetidine-2-carboxylic acid. (C)Osteoligamentcells
treated with 43°C heat for 90 min. (D) Canine ligament cells ex-
posed to 100 mM sodium arsenite for 1.5 hr. (E) Osteoligament
cells challenged with 45°C heat for 30 min. (F) Canine ligament
cells grown in the presence of ionophore A23187 for 8 hr.
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ing (41); g) GC box, SP1 binding (42); h) an imperfect
palindrome as a possible stem loop structure; and i)
GAGA box, a Si-one endonuclease recognition site
(34).
Wehave demonstratedthatalthoughthe osteonectin
gene contains a heat shock element, osteoligament
cells challenged with 450C for 30 min do not respond
with enhanced mRNA production. Interestingly, the
levels ofmRNAremain stable andthe cellular levels of
protein synthesis increase 2-fold. In contrast, L-aziti-
dine-2-carboxylic acid, an amino acidanalog, knownto
induce a variety of stress and heat shock proteins,
lowers both cellular cells ofosteonectin (Fig. 1) and its
mRNA. Sodium arsenite significantly enhances osteo-
nectin mRNA levelsbutdepresses cellular levels ofthe
protein, suggesting that stability ofthe message may
be altered with exposure to these agents.
In addition to these agents, a number of environ-
mental and pharmacological agents have been shown
to affect the expression of osteonectin/SPARC. Retin-
oic acid and dibutyryl-cAMP have been shown to en-
hance the production osteonectin and mRNA 40-fold
(29). Low doses of tumor-derived growth factor has
beenshowntoincrease osteonectinmRNAinROS 17/2
cells 2- to 3-fold (36). Conversely, parathyroid hormone
decreased osteonectin mRNA levels inUMR-106-01 os-
teosarcoma cells (34), while 1,25-dihydroxyvitamin D3
appears to down regulate its expression in cultured
human bone cells (43). Finally, viral transformation
has been shown to drastically reduce osteonectin
mRNA levels in chick (44), mouse, and a number of
tumors (30).
Thus, all evidence to date indicates that osteonectin
is under tight regulation and is associated with areas
ofrapidtissue remodeling(45,46). As such, the protein
or its mRNA have been localized in the stroma of
breast and gastric carcinomas, the basement mem-
branes about tumor islands, and in expanding human
decidua (47).
Attachment Proteins
Attachment proteins, by modulating cell-cell or cell-
substratum interactions, alter diverse biological pro-
cesses including embryonic development, wound heal-
ing, tumor cell metastasis, and tissue regulation. The
potential significance ofsuchproteins inthe regenera-
tion ofcell behavior has resulted in increasing efforts
to identify and understand the properties of attach-
ment proteins (48,49). A common RGD (arg-gly-asp)-
peptide sequence has been identified in the region as-
sociated with cell attachment in several ofthese pro-
teins, e.g., fibronectin, vitronectin, bone sialoprotein I,
andbone sialoprotein II (49). In addition, the ability of
these same proteins to promote cell migration may be
regulated through the domain containing the RGD-
peptide sequence (49,50). Attachment of cells to such
proteins involves interactions with specific cell surface
glycoprotein receptors. While these receptors are dis-
tinct, they have been shown to be structurally and
functionally related, belonging to a superfamily ofre-
ceptors called integrins. Structurally these receptors
appear similar, containing heteromeric complexes of
noncovalently associated alpha and beta subunits
(48,49). Theintegrin receptorsrequire divalent cations
to function; that is in the absence of divalent cations,
the receptor cannot bind to its ligand (51). Thus, any
metal, e.g., lead, that has the potential to alter recep-
tor-ligand interactions may prevent cell attachment
and spreading.
While proteins that alter the attachment properties
ofcells have been identified intissues otherthanbone,
it is not until recently that such proteins have been
identified in bone. Initial studies in our laboratory
showed that bone cells, unlike Chinese hamster ovary
(CHO) cells, become attached to plates preincubated
with fibronectin-free serum, leading us to speculate
thatbonecellssynthesize aproteinthatmodulatescell
attachment (52). We also demonstrated that guani-
dine/EDTA extracts ofdemineralized tissues promote
attachment of gingival fibroblasts in vitro (53). More
recently, incollaborationwithW. ButlerandC. Prince,
we identifiedtwofractions, afterDEAE-Sephacel chro-
matography ofrat bone EDTA extract, that markedly
promoted attachment and speading of gingival fibro-
blasts(16). Afterfurtherpurificationfromratbone(54)
and human developing bone (20), these proteins, iden-
tified as bone sialoprotein I (BSP I) and as bone sialo-
protein II (BSP II),* were shown to have attachment
activity (16-18,55,56). Discussed below are some char-
acteristicsandproperties ofBSPIandBSPII. Alsodis-
cussedisboneacidicglycoprotein-75(BAG-75), aprotein
isolated from rat bone, reported to have attachment
activity (14). All three attachment proteins are sialic
acid-rich phosphorylated glycoproteins.
Sialicacid-rich noncollagenousproteinsofbonewere
first identified in the 1950s as a direct result of at-
tempts to detect molecules in bone that bind radioac-
tive elements from the atomic bomb test fallout.
Vaughn (57) showed that plutonium was located in
areas ofbone staining with periodic acid-Schiff(PAS),
suggestingbindingto noncollagenous molecules. Sub-
sequently, Herring and Kent (58) isolated and charac-
terized a cation-binding glycoprotein from adult bovine
bone. This protein, which they called bone sialopro-
tein, was20%byweightsialicacidandhadamolecular
weight ofapproximately 25,000 Da. Two decades later,
using protease inhibitors and denaturing solvents,
Fisher et al. (20,59) showed that the 25 kDa protein
was a degradation product ofa larger protein, BSP II.
BSP II has been purified andpartially characterized
from developing calf bone (59), bovine bone (60), rat
bone (15), and developing human bone (20). The intact
*Throughout this article BSP I is used to designate bone sialopro-
tein I, also called osteopontin, 44 kDa bone phosphoprotein, 2ar,
SppI andtumor-secreted phosphoprotein. BSPII isusedtodesignate
bone sialoprotein II, also called BSP (bone salioprotein). BAG-75 is
used to designate bone acidic glycoprotein-75.
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protein, purified frombovine and human tissues, is 70
to 80 kDa on SDS gels stained with Alcian blue. BSP
II does not stain with Coomassie blue unless the sialic
acid residues are removed with neuraminidase (20),
Human BSP II contains approximately 50% protein,
12% sialic acid, 7% glucosamine, and 6% galactosa-
mine. Rat BSP II appears to have a lower molecular
weight, 57 kDa, and contains approximately 5% sialic
acid(60). DNA sequence analysisindicatedthatBSPII
contains anRGD-peptide sequence (15),whichpresum-
ably isresponsible foritsabilitytopromotecell attach-
ment (15,18). Except for this conserved RGD-peptide
sequence,BSPIIshowsnostructural similaritytoBSP
I. The region surrounding the RGD-peptide sequence
was shown to be similar to the RGD region in vitro-
nectin (15). This includes 9 identical residues and 3
conserved substitutions in a region of24 residues. No
homologies inthisregiontoother attachment proteins
were reported. Preliminary studies on the localization
of BSP II in tissues by in situ hybridization studies
indicate that BSP II is more selective for bone tis-
sues, when compared with BSP I (M. Young, personal
communication).
In our laboratories we have been evaluating BSP II
for its attachment activity for cells ofperiodontal ori-
gin. Cells ofthe periodontium are considered to have
thecapacity to stimulate regeneration oftheperiodon-
tium, e.g., bone, cementum, and dentin (61). BSP II
promotes gingival fibroblast attachment and RGD-
peptidesblock this activity (18). Also, a keratin sulfate
proteoglycan isolatedfromrabbitbone, where the core
protein isknowntobe BSP II(62), enhancedfibroblast
cell attachment. Pretreatment of this proteoglycan
withkeratinaseenhancedthisactivityfurther(unpub-
lished data). BSP II does not promote attachment of
A431 epithelial cells (18). Oldberg et al. (63) isolated
the cell receptor for BSP II using osteosarcoma cells,
ROS 17/2.8, cells known to exhibit enhanced attach-
ment in the presence ofBSP II(15). This protein recep-
tor isremarkably similar ifnot identical to aprevious-
ly characterized vitronectin receptor (64) and binds
both vitronectin and BSP II. Further studies directed
atdeterminingifotherbonecells, e.g., osteoclasts, non-
tumorigenic osteoblasts, have specific receptors for
BSP II and will provide information ofthe specificity
ofBSP II receptor interactions.
Bone sialoprotein I was the first bone protein to be
recognized as having attachment activity and has
beengivenseveraldifferent names, whichinclude a)44
kDa bone phosphoprotein (44 kDa BPP), based on mo-
lecular weight sedimentation equilibrium (54), b) os-
teopontin, suggesting a bridging potential between
cellsandmineral inbone(15); c)2ar, atumorpromoter-
inducible protein secreted by mouse JB6 epidermal
cells (65), now recognized as the murine homologue of
ratBSPI(66); d)mouse secretedphosphoprotein I(Spp
I) (67); and e) tumor-secreted phosphoprotein. Most re-
cent evidence suggests that a phosphoprotein, 62 K
(varying depending on species), secreted by spontane-
ously transformed cells (68,69) is related ifnot identi-
cal to BSP I. Elevated secretion of this protein was
reported for tumor cells (68,69) as well as plasma and
sera from patients with disseminated carcinomas and
with gram negative sepsis (68).
BSP I isolated from a variety ofmineralized tissues,
e.g., ratbone (15), developingcalfbones (59), anddevel-
oping human bone (20), appear to be very similar to
eachother.BSPI(= 68,000 molecularweightdepending
on species) is a glycoprotein, rich in aspartic acid and
glutamicacid,containing 12residuesofphosphoserine
and one of phosphothreonine (54). cDNA sequencing
studiesindicatethatthisproteincontains anRGDcell
attachment sequence (15). Carbohydrate, approximate-
ly 17% ofthe mass ofthe molecule, including about 10
residues ofsialic acid, is present as 1 N-glycoside and
5 to 6 O-glycosides (54). Secondary structure analysis
by Prince et al. (70) indicate BSP I, like osteonectin,
contains an EF hand, representing a calcium binding.
site. As predicted for fibronectin, the cell attachment
site in BSP I is located in a beta turn. BSP I also has
a run of 9 aspartic acid residues (70) suggested to
contribute to its tight binding to hydroxyapatite (15).
Young et al. (71) have shown that the genes for both
human BSP I and human BSP II are located on chro-
mosome4,whileFetetal.(67)localizedthemousegene
for BSP I to chromosome 5.
Prince etal. (72)establishedthat osteosarcomacells,
ROS 17/2.8 cells, synthesize and secrete BSP I. Subse-
quent studies showed that BSP I production by bone
cells in vitro can be modulated by several factors. The
production ofBSP I and BSP I mRNA are enhanced in
ROS 17/2.8 cells exposed to 1,25-dihydroxyvitamin D3
(72,73). In addition, transforming growth factors beta
(74), glucocorticoids (73), and parathyroid hormone
regulate expression ofBSP Iby bone cells(74). Studies
involved with evaluating the expression of BSP I by
othercellsindicatedthatinepidermalcells12-O-tetra-
decanoylphorbol-13-acetate (TPA) increases the expres-
sion ofthis protein. In vitro tumorigenic cells secrete
10-fold or more BSP I when compared with similar
nontumorigenic cells (66,68,69). These studies impli-
cate this protein as having a role in regulating tumor
growth in vivo.
Immunohistochemical analysis (75-77) and in situ
hybridization studies of BSP I or its mRNA indicate
that this protein is present in bone, osteoid, and osteo-
blasts, as well as cells considered to be precursors to
osteoblasts or cells ofhemopoietic origin. High levels
ofBSP I or its mRNA are also observed in kidney, se-
cretory epithelium, and ganglia ofthe developing ear,
in brain, and in bone marrow-derived granulated met-
rial gland cells in the uterus and decidium (46,78).
Thus, it is evident that the biochemical functions of
BSP I are not limited to mineralized tissues.
Independent studies by Somerman et al. (16,79,80)
and Oldberg et al. (15) indicated that BSP I promotes
the attachment and spreading of osteoblastlike cells,
aswell as avariety ofother cell types in vitro. Detailed
studies on the attachment properties ofBSP I suggest
properties particular to this protein when compared
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thatobservedwithcontrolcells(80). Atpresentitisnot
known whether BSP II or BAG-75 have migration
activity.
Thus, the persistent effect of BSP I on cell attach-
ment may in partbe relatedto its inability to promote
cell migration. In attempts to better understand the
mechanisms regulating BSP I-mediated cell attach-
ment, we evaluated protein production by fibroblasts
after exposure to BSP I under normal tissue culture
conditionsorwhenexposedto45°C temperature. Apo-
tentially important finding is that fibroblasts grown
on BSP I-coated dishes exposed to 450C temperature
for 30 min maintain attached and spread appearance.
In contrast, a significant number ofcells grown on fi-
bronectin-coated dishes become rounded and/or de-
tached after the 450C treatment (Fig. 3). In addition,
over a 24 hr time period, cells grown on BSP I-coated
dishesexhibitenhancedtotalproteinproductionwhen
comparedwithcells grown onfibronectin-coated ortis-
sue culture dishes (unpublished data). In support of
these findings, previous studies by Polla et al. (81)
showed the 1,25-dihydroxyvitamin D3, a hormone now
knowntoincreasetheproductionofBSPIinbonecells,
maintains the adherence of monocytes to tissue cul-
ture dishes and protects them from thermal injury.
Futhermore, Gronowiczetal.(82)reportedthat 1,25-di-
hydroxyvitamin D3 had pronounced effects on cell
shapeinosteoblasticcells,probablyviade novoprotein
synthesis. The evidence that 1,25-dihydroxyvitamin
D3 can modulate the functions of mononuclear cells
(83,84) together with the ability ofthis hormone to in-
crease theproductionofBSPI incertaincells suggests
that 1,25-dihydroxyvitamin D3 may, in part, be exert-
ingitseffects oncell adherencebystim'ulatingthe pro-
duction ofBSP I.
Recently, Gorski andShikizu(14)extracted andpuri-
fied aproteinfrom ratbone, bone acidic glycoprotein-75
FIGURE 2. Fibroblast attachment and spreading on uncoated dishes
(CN) or dishes coated with BSP I or fibronectin (FN) at 24 hr.
with otherattachment proteins. BSPIhas apersistent
effect on cell attachment. BSP I promotes fibroblast
cell attachment and spreading for more than 8 days
(18). In contrast, cells exposed to BSP II or fibronectin,
while demonstrating enhanced attachment and
spreading short term(up to 6 hr) exhibit a rounded ap-
pearance, associated with decreased cell attachment
by 24 hr (Fig. 2). In addition, while fibronectin en-
hances fibroblast attachment on collagen substrata,
BSP I has no effect beyond that observed with cells ex-
posed to collagen-coated dishes (16). To date a collagen
domain has not been identified for BSP I, suggesting
that in addition to BSP I, other molecules are involved
in attachment of osteoblastic cells to osteoid, a pre-
dominantlytypeIcollagenmatrix. Furthermore,fibro-
nectin promotes the migration of gingival fibroblast,
while BSP I does not stimulate cell migration beyond
CN BSP I
-- l g_.. SIV ::; _Nta 3e
FN
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FIGURE 3. Effect of substrata on response of fibroblasts to heat
stress. Cells were allowedto attach ontissueculture dishes(CN),
or dishes coated with BSP I, BSP II, or fibronectin(FN)for 24 hr,
and then cells were exposed to 45°C temperature for 30 min.
CN
BSP I
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(BAG-75)which is a 75,000 molecular weight phospho-
protein containing 7% sialic acid. N-terminal sequence
analysis showed that BAG-75 is unique, although a
33% homology to BSP I was noted. In addition, they
have shownthat this protein promotes osteoblastic ad-
herence (J. P. Gorski, personal communication).
The question still remains as to the role of these
bone-associated attachment proteins inthe regulation
of bone homeostasis, as well as the possible role for
these proteins in other tissues. All three ofthese pro-
teins have a strong affinity for calcium, suggesting a
common role for these proteins in the transport and
storage ofcalcium. Asto apotentialfunctioninattach-
mentofcells atanappropriate site in vivo,the question
arises as to the need for these attachment proteins in
bone. In this regard our in vitro studies suggest that
BSP I and BSP II function differently, e.g., only BSP I-
mediated fibroblast attachment in a persistent man-
ner. Recent investigation points to a correlation be-
tween shape and attachment ofcells and the nature of
the expressed gene products. Forexample, attachment
ofcellsto asubstratum is necessaryforprotein synthe-
sis (translational control) (85). Thus it is interesting
that some attachment proteins, e.g., thrombospondin,
promote attachment but not spreading of certain cell
types(86). Ourfindingsthat BSPI, but notfibronectin
or BSP II, persistently promotes cell attachment and
spreading suggests a unique and separate function for
these proteins. These findings may provide clues as
to the function of bone-associated BSP I in vivo. For
example, in fracture healing after migration ofappro-
priate cells into the wound site, BSP I may allow for
significant cell numbers to stay at the site. This would
provide increased production of extracellular matrix
required for bone formation. Further, the inability of
thesecellstomigratemayallow such cells tobe imbed-
ded inthe bone matrixtofunction as osteocytes. Other
possible functionsforBSPIinclude maintaining apop-
ulation ofmonocytes at an inflammatory site, as well
as a role in regulating blood clotting.
Studies directed at understanding the interaction of
bone-associated attachment proteins with specific
cells and identifying specific cell receptors for these
proteins will help to clarify the role of these attach-
ment proteins in the modulation oftissue function.
The importance of calcium in regulating protein-
mediated cell attachment suggests that any metals
that can substitute (compete) for calcium, e.g., lead,
can alter cell-cell and cell-substratum interactions.
Another concern is that metals may alterthe hydroxy-
apatite crystal thus altering bone cell attachment to
the mineralized matrix. In addition, certain metals
may compete with calcium at calcium binding sites
andsubsequently alterproteinfunction, aswell ascal-
cium homeostasis. The effects oflead may not only be
seen in mineralized tissues, but also in other tissues
where calcium-binding bone-associated proteins, e.g.,
osteonectin and BSP I, have been identified. Studies
addressing such issues are currently beingdesigned in
our laboratories.
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